Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    MERTK
Show Display Options
Rank Status Study
1 Recruiting Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations
Condition: Retinal Disease
Intervention: Genetic: Recombinant Adeno-Associated Virus

Indicates status has not been verified in more than two years